Pricing Log in Create free account
Friday 6 November 2026 Export BDX’s income statement to Excel — free account

Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

Revenue
−10.5%
EPS
+48.5%
Free cash flow
−31.6%
Total debt
−23.8%

Quarter to September 2026, against a year earlier

212.21 1.34 −0.63%
Market cap
$58.2B
P/E
51.1×
Fwd P/E
39.2×
Dividend yield
1.87%
F-score
6/9
Altman Z
n/a
Beneish M
−2.76
Dividend safety
51/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Becton, Dickinson and Company 10-Q filed May 7, 2026

Fiscal Q2 2026 · Period ended Mar 31, 2026 · Filed · accepted 4:34 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Feb 9, 2026: 19 added · 17 removed · 74 modified; 20 with only figures updated

  1. Modified · Company Overview

    Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products devices used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.